Capital Growth Management LP Eli Lilly & CO Transaction History

Capital Growth Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$146.22 - $169.13 $10.2 Million - $11.8 Million	-70,000 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$136.42 - $164.18 $8.19 Million - $9.85 Million	60,000 Added 600.0%	70,000 $11.5 Million
Q1 2020 May 15, 2020	BUY	$119.05 - $147.35 $1.19 Million - $1.47 Million	10,000 New	10,000 $1.39 Million
Q1 2019 May 15, 2019	SELL	$111.31 - $131.02 $5.57 Million - $6.55 Million	-50,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$105.9 - $118.64 $37.6 Million - $42.1 Million	-355,000 Reduced 87.65%	50,000 $5.79 Million
Q3 2018 Nov 09, 2018	BUY	$85.86 - $107.31 $34.8 Million - $43.5 Million	405,000 New	405,000 $43.5 Million

4,010

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Capital Growth Management LP, based on Form 13F filings with the SEC.

Stay updated on Capital Growth Management LP with notifications on news.